31![Shionogi & Co., Ltd. Shionogi & Co., Ltd. to Acquire the Shares and to Conduct a General Offer for China-based C&O Pharmaceutical Technology (Holdings) Limited Osaka, Japan, August 18, Shionogi & Co., Ltd. (Head Shionogi & Co., Ltd. Shionogi & Co., Ltd. to Acquire the Shares and to Conduct a General Offer for China-based C&O Pharmaceutical Technology (Holdings) Limited Osaka, Japan, August 18, Shionogi & Co., Ltd. (Head](https://www.pdfsearch.io/img/fd5004212ce622f56aea2aee59d7c122.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:17
|
---|
32![Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S](https://www.pdfsearch.io/img/23315319e0e6ab8409732bdb66460d32.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:22
|
---|
33![Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1 Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1 ](https://www.pdfsearch.io/img/e68e47ccac33fb828cf030b79caf1753.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|
34![Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1](https://www.pdfsearch.io/img/63a3f4cfdde2c9a4153687d59f202349.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-01-27 15:09:34
|
---|
35![Shionogi & Co., Ltd. Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type- Osaka, June 1, 2010 – Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; he Shionogi & Co., Ltd. Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type- Osaka, June 1, 2010 – Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; he](https://www.pdfsearch.io/img/6a0ad445a94823e94930e93c6e7b870f.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:17
|
---|
36![Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I](https://www.pdfsearch.io/img/f2edba1b703eb36b34072d7f4ded7f54.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:11
|
---|
37![April 16, 2010 Shionogi & Co., Ltd. Eli Lilly Japan K.K. Launch of an Antidepressant Drug, “Cymbalta® Capsules 20mg and 30mg” Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “ April 16, 2010 Shionogi & Co., Ltd. Eli Lilly Japan K.K. Launch of an Antidepressant Drug, “Cymbalta® Capsules 20mg and 30mg” Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “](https://www.pdfsearch.io/img/c2cdf337d734d9eed185f354505dd4de.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|
38![February 15, 2010 Shionogi & Co., Ltd. Shionogi Files an Additional Application for Pediatric Use of “RAPIACTA®’’ a Novel Anti-viral Drug for Influenza February 15, 2010 Shionogi & Co., Ltd. Shionogi Files an Additional Application for Pediatric Use of “RAPIACTA®’’ a Novel Anti-viral Drug for Influenza](https://www.pdfsearch.io/img/e52803bdb7353957de819a65a51248bd.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|
39![Antitrichomonal Agent, Flagyl® Approval for Additional Indication of Bacterial Vaginosis Osaka, Japan, March 21, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shio Antitrichomonal Agent, Flagyl® Approval for Additional Indication of Bacterial Vaginosis Osaka, Japan, March 21, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shio](https://www.pdfsearch.io/img/cdd0b3c4091d32c135c031d46549e8c8.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:19
|
---|
40![Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis Pneumonia Osaka, Japan, August 10, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis Pneumonia Osaka, Japan, August 10, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO](https://www.pdfsearch.io/img/39149cc69fec0a7f26c8d5c1f4dac263.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|